Skip to content
10-Q

Quarterly Report

SPRINGWORKS THERAPEUTICS, INC.

0001773427-24-000018

← back to feed
Filed
May 2, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Apr 26, 2024 74.09M sh
Cash And Equivalents Q1 2024 · Mar 31, 2024 $118.03M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $176.05M
Current Liabilities Q1 2024 · Mar 31, 2024 $68.92M
Current Liabilities Q1 2024 · Dec 31, 2023 $78.17M
Total Liabilities Q1 2024 · Mar 31, 2024 $89.39M
Total Liabilities Q1 2024 · Dec 31, 2023 $99.57M
Current Assets Q1 2024 · Mar 31, 2024 $471.8M
Current Assets Q1 2024 · Dec 31, 2023 $500.91M
Total Assets Q1 2024 · Mar 31, 2024 $656.83M
Total Assets Q1 2024 · Dec 31, 2023 $725.79M
Shares Diluted Q1 2024 · Mar 31, 2023 62.33M sh
Stock Repurchased Q1 2024 · Mar 31, 2023 $1.93M
Capex Q1 2024 · Mar 31, 2023 $2.98M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$61.82M
Stockholders Equity Q1 2024 · Mar 31, 2023 $506.92M
Stockholders Equity Q1 2024 · Dec 31, 2022 $558.19M
Eps Diluted Q1 2024 · Mar 31, 2023 −$1.18
Eps Basic Q1 2024 · Mar 31, 2023 −$1.18
Sga Expense Q1 2024 · Mar 31, 2023 $44.18M
Rd Expense Q1 2024 · Mar 31, 2023 $33.52M
Net Income Q1 2024 · Mar 31, 2023 −$73.42M
Operating Income Q1 2024 · Mar 31, 2023 −$77.7M
Cost Of Revenue Q1 2024 · Mar 31, 2023 $0